AstraZeneca (AZN) and Merck (MRK), known as MSD outside of the United States and Canada, announced that LYNPARZA has been approved in the European Union in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated. This approval by the European Commission follows the positive recommendation from the Committee for Medicinal Products for Human Use received in November this year and was based on the Phase 3 PROpel trial, results of which were published in NEJM Evidence in June 2022.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Top 10 Dividend Growth Stocks and How to Choose Them
- Seagen, Astellas and Merck announce FDA acceptance of sBLA in urothelial cancer
- Astellas, Seagen, and Merck announce priority review for Padcev and Keytruda
- Merck price target raised to $128 from $110 at Barclays
- Merck price target raised to $135 from $120 at Cantor Fitzgerald